- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 720
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- aldesleukin, ipilimumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveal Melanoma
- Interventions
- ADI PEG20, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
- Interventions
- None-Observation Only
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 997 participants
- Timeline
- 2003 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Interventions
- NN3201
- Drug
- Lead sponsor
- Novelty Nobility, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
- Conditions
- Neuromyelitis Optica
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neuromyelitis Optica
- Interventions
- Scrambler, Scrambler Sham Control
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Uveal Melanoma
- Interventions
- Intraoperative ultrasonography
- Procedure
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Carcinoid, Neuroendocrine
- Interventions
- Seneca Valley Virus (biological agent)
- Drug
- Lead sponsor
- Neotropix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more
- Conditions
- Normal Tension Glaucoma (NTG)
- Interventions
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Ocular Inflammation, Crystalline Lens; Chalcosis, Intraocular Lens Complication
- Interventions
- Cymbathera One System
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Biological Clock Dysfunction, Optic Nerve Hypoplasia
- Interventions
- Melatonin, Placebo Comparator
- Dietary Supplement
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Years to 10 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Interventions
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
- Drug · Device
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 32
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 27 more
- Conditions
- Neuromyelitis Optica Spectrum Disorder, NMOSD
- Interventions
- Satralizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
- Interventions
- Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan
- Drug
- Lead sponsor
- Julie Krystal
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Optic Neuritis
- Interventions
- Lipoic Acid
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Pyruvate, creatine, niacinamide, Placebo
- Dietary Supplement
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Leber Hereditary Optic Neuropathy
- Interventions
- Patient-reported outcomes (PROs)
- Other
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Pasadena, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2070
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
- Interventions
- Visual Performance tests, Brain-computer interface
- Diagnostic Test · Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Intraocular Melanoma
- Interventions
- fluorescence in situ hybridization, laboratory biomarker analysis, fine-needle aspiration, therapeutic conventional surgery, Questionnaires
- Genetic · Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Refractive Errors, Amblyopia, Strabismus, Development Delay
- Interventions
- 2WIN photoscreener
- Device
- Lead sponsor
- Alaska Blind Child Discovery
- Other
- Eligibility
- 1 Week to 90 Years
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Interventions
- IDE196, Binimetinib, Crizotinib
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
- Conditions
- Anterior Ischemic Optic Neuropathy
- Interventions
- Diagnostic procedures
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 11
- States / cities
- Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more